Why is this study being conducted?
This study is testing a new investigational vaccine for Chlamydia trachomatis (Ct) infection. The purpose of this study is to determine if the study vaccine is safe, efficacious in preventing and protecting against a Chlamydia infection, and will produce an immune response.
Who is eligible to participate in this study?
You may be eligible if you are:
- Aged 18 - 29 years
- Sexually active
- Able to attend all scheduled visits
Those who are interested in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be 1.5 years and participants will have 10-13 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will receive 3 doses of the Chlamydia vaccine.
You will have 2-4 safety phone calls.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Subaat Khan
To learn more about this clinical trial, please contact:
Subaat Khan, Clinical Trial Coordinator.
0481 277 676 clinicaltrialunit@griffith.edu.au
Ethics approval number for the Chlamydia Vaccine Trial: Bellberry Limited 2024-11-1717, GU HREC 2025/180
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials